

Form 51-102F3
Material Change Report

1. Name and Address of Company

Nova Mentis Life Science Corp.
700-838 W Hastings Street
Vancouver, BC, V6C 0A6

(the "Company")

2. Dates of Material Change(s)

June 10, 2021

3. News Release(s)

A news release was issued on June 10, 2021 and disseminated via Cision pursuant to section 7.1 of National Instrument 51-102.

4. Summaries of Material Changes

The Company announces that it Company has entered into a debt settlement agreement pursuant to which the Company has agreed to issue 1,513,306 common shares, at a deemed price of \$0.08 per Share, to settle indebtedness of \$121,064.52.

5. Full Description of Material Changes

News Release dated June 10, 2021– See Schedule "A"

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been omitted.

8. Executive Officer

Mr. Will Rascan, President and CEO of the Company, is knowledgeable about the material change contained herein and may be reached at (778) 819-0244.

9. Date of Report

This report is dated June 10, 2021.

SCHEDULE "A"
to the Material Change Report June 10, 2021

**Nova Mentis to Present
at the H.C. Wainwright Psychedelics Conference**

Vancouver, British Columbia – June 10, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be presenting at the H.C. Wainwright *Psychedelics in Psychiatry and Beyond* virtual conference on June 17, 2021.

"The conference is a great opportunity to discuss the potential for psychedelics to treat debilitating diseases that are not being met through traditional medicine, in the field of neuroinflammatory disorders such as Parkinson's disease, multiple sclerosis, PTSD and especially autism spectrum disorder (ASD)," says Dr. Marvin S. Hausman, Chairman of NOVA's Scientific Advisory Board.

In his address, Dr. Hausman will be discussing the approach NOVA will use for regulatory approval of its proprietary psilocybin and other tryptamine derivative formulations. Recent positive preclinical and safety data will also be revealed, as well as ongoing regulatory submission steps with the U.S. FDA and the European Medical Authority (EMA).

His [presentation](#) will be available on-demand starting at 7:00 a.m. EST on June 17, 2021. [Click here](#) to register for the conference and schedule a one-on-one meeting with Dr. Hausman.

The Company is currently conducting a large-scale [observational study](#) to assess the gut microbiome, immune/inflammatory response and serotonin activity, as all these systems are likely involved in producing the variety of behavioural symptoms observed in ASD and fragile X syndrome (FXS). The research will lead to the development of a set of biomarkers to help differentiate subsets of symptomatic, as well as pre-symptomatic, ASD and FXS patients – an approach that currently does not exist in clinical practice.

Further, the Company has entered into a debt settlement agreement pursuant to which the Company has agreed to issue 1,513,306 common shares (each, a "Share"), at a deemed price of \$0.08 per Share, to settle indebtedness of \$121,064.52 (the "Transaction"). All Shares issued pursuant to the Transaction are subject to a statutory four-month and one-day hold period.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit <https://www.novamentis.ca> or email info@novamentis.ca.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc